×
About 1,420 results

ALLMedicine™ Inflammatory Breast Cancer Center

Research & Reviews  446 results

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT02876107

Jun 24th, 2022 - PRIMARY OBJECTIVES: I. To determine the pathologic complete response (pCR) rate in patients with primary triple-receptor negative (estrogen receptor [ER]-negative, progesterone receptor [PgR]-negative, and human epidermal growth factor receptor 2 ...

Inflammatory Breast Cancer: The Cytokinome of Post-Mastectomy Wound Fluid Augments Prol...
https://doi.org/10.3390/cimb44060187
Current Issues in Molecular Biology; Tarek A, El-Sayed SK et. al.

Jun 24th, 2022 - Inflammatory breast cancer (IBC) is an aggressive phenotype with a high recurrence and low survival rate. Approximately 90% of local breast cancer recurrences occur adjacent to the same quadrant as the initial cancer, implying that tumor recurrenc...

Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT03598257

Jun 22nd, 2022 - PRIMARY OBJECTIVE: I. To compare the invasive disease-free survival (IDFS) of patients with inflammatory breast cancer receiving concurrent administration of olaparib with standard doses of radiotherapy to the chest wall and regional lymph nodes c...

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT05177796

Jun 21st, 2022 - PRIMARY OBJECTIVE: I. To determine the pathological complete response (pCR rate) of the proposed combination in patients with newly diagnosed triple-negative inflammatory breast cancer (TN-IBC). SECONDARY OBJECTIVES I. To evaluate the surgical com...

Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2022.0030
Journal of the National Comprehensive Cancer Network : JN... Gradishar WJ, Moran MS et. al.

Jun 18th, 2022 - The therapeutic options for patients with noninvasive or invasive breast cancer are complex and varied. These NCCN Clinical Practice Guidelines for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, i...

see more →

Guidelines  1 results

International expert panel on inflammatory breast cancer: consensus statement for stand...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3105293
Annals of Oncology : Official Journal of the European Soc... Dawood S, Merajver SD et. al.

Jul 7th, 2010 - Inflammatory breast cancer (IBC) represents the most aggressive presentation of breast cancer. Women diagnosed with IBC typically have a poorer prognosis compared with those diagnosed with non-IBC tumors. Recommendations and guidelines published t...

see more →

Clinicaltrials.gov  67 results

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT02876107

Jun 24th, 2022 - PRIMARY OBJECTIVES: I. To determine the pathologic complete response (pCR) rate in patients with primary triple-receptor negative (estrogen receptor [ER]-negative, progesterone receptor [PgR]-negative, and human epidermal growth factor receptor 2 ...

Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT03598257

Jun 22nd, 2022 - PRIMARY OBJECTIVE: I. To compare the invasive disease-free survival (IDFS) of patients with inflammatory breast cancer receiving concurrent administration of olaparib with standard doses of radiotherapy to the chest wall and regional lymph nodes c...

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT05177796

Jun 21st, 2022 - PRIMARY OBJECTIVE: I. To determine the pathological complete response (pCR rate) of the proposed combination in patients with newly diagnosed triple-negative inflammatory breast cancer (TN-IBC). SECONDARY OBJECTIVES I. To evaluate the surgical com...

Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT00477100

Apr 29th, 2022 - PRIMARY OBJECTIVES: I. To prospectively collect tissue (including primary inflammatory breast cancer [IBC], ipsilateral nodal metastasis and/or distant metastasis [if applicable] obtained prior to primary systemic therapy and mastectomy/axillary d...

Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body
https://clinicaltrials.gov/ct2/show/NCT05198843

Apr 13th, 2022 - PRIMARY OBJECTIVES: I. To determine maximum tolerated dose (MTD) of icosapent ethyl (EPA) and dasatinib in patients with metastatic triple negative inflammatory breast cancer (mTN-IBC). (Phase 1b) II. To determine the overall response rate (ORR) o...

see more →

News  47 results

In Historic Vote, ODAC Suggests Approval of Neoadjuvant Pertuzumab Regimen
https://www.onclive.com/view/in-historic-vote-on-pertuzumab-odac-suggests-approval-of-first-neoadjuvant-regimen-for-cancer

Mar 15th, 2022 - Mikkael Sekeres, MD, MS The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 13-0 with one abstention in support of pertuzumab (Perjeta) in combination with trastuzumab and docetaxel for patients with HER2-positive breast cancer in the neoad...

Sentinel-Lymph-Node Biopsies Rising in Patients With Inflammatory Breast Cancer, Against Guidelines
https://www.medscape.com/viewarticle/968517

Feb 17th, 2022 - NEW YORK (Reuters Health) - Sentinel-lymph-node biopsies are frequently and increasingly being used in patients with inflammatory breast cancer, contrary to guidelines which recommend axillary-lymph-node dissection for these women, a new study sho...

Novel CDK 4/6 Inhibitor Explored in Premenopausal Breast Cancer Setting
https://www.onclive.com/view/novel-cdk-46-inhibitor-explored-in-premenopausal-breast-cancer-setting

Oct 6th, 2021 - Debu Tripathy, MD Although targeting cyclin-dependent kinase (CDK) 4/6 has proved to be a successful strategy in the management of postmenopausal women with hormone receptor (HR)— positive, HER2-negative advanced breast cancer, there is an unmet ...

Dr. Connolly on Potential Benefit of Postmastectomy Radiation for Breast Cancer
https://www.onclive.com/view/dr-connolly-on-potential-benefit-of-postmastectomy-radiation-for-breast-cancer

Oct 6th, 2021 - Eileen Connolly, MD, PhD, an assistant professor of radiation oncology at Columbia University Medical Center, discusses the possible benefit of postmastectomy radiation for patients with breast cancer. Postmastectomy radiation has traditionally b...

Enobosarm Shows Clinical Benefit in AR+, ER+ Metastatic Breast Cancer
https://www.onclive.com/view/enobosarm-shows-clinical-benefit-in-ar-er-metastatic-breast-cancer

Oct 6th, 2021 - Enobosarm demonstrated clinical benefit at varying dose levels in patients with androgen receptor (AR)–positive, estrogen receptor (ER)–positive metastatic breast cancer, according to phase 2 findings of the G200802 study that were presented durin...

see more →

Patient Education  7 results see all →